One mechanism underlying the anti-oncogenic effect of FHL2 silencing could be the decreased expression of the Wnt family members Wnt5a and Wnt10b that we observed in vitro and in vivo, because these proteins confer cell invasiveness, metastasis and reduced survival in osteosarcomas [22], [23], [24] and thereby contribute to tumorigenesis [49], [50]. This evidence concerns the gene WNT10B and osteosarcoma.